- Dr. Dan Douer of MSKCC presented data at the 2012 Chemotherapy Foundation Symposium from a pivotal Phase 2 RALLY trial of Marquibo. Marqibo is indicated for the treatment of adult patients with Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.
- The New Times reports that MSKCC has agreed to train Rwandan public and private medical personnel on cancer treatment and management.
Author Archives: Mark
MSKCC in the News: August 29 – September 19
- Last week Mayor Bloomberg, MSKCC, CUNY and Hunter College announced plans to build two new science and medical facilities on the Upper East Side.
- The New York Times reported that veterinarians from the Animal Medical Center began meeting with their counterparts at MSKCC to set up trials of a noninvasive device for removing tumors of the urinary tract with electrical impulses.
- Acupuncture for the treatment of chronic pain is better than placebo acupuncture (sham acupuncture) or no acupuncture at all, researchers from MSKCC wrote in the JAMA journal Archives of Internal Medicine.
- In a recent study published in the New England Journal of Medicine, MSKCC’s Howard I. Scher and colleagues found that men with metastatic castration-resistant prostate cancer after chemotherapy have improved survival and secondary end points after treatment with enzalutamide vs. placebo.
Elsevier eJournals, Scopus, SciVal Scheduled Outage
Elsevier has announced that ScienceDirect, Scopus, Hub, Applications, SciVal, and Journals Consult are expected to be unavailable due to scheduled maintenance from 7:30AM Saturday, August 25th to 2:30AM on Sunday, August 26th, 2012. During this time, upgrades will be implemented and maintenance performed.